All tracked trials

Phase 2 and Phase 3 cancer trials run by companies on the Nasdaq or New York Stock Exchange.

1,669 trials · most recently edited first

GSKGlaxoSmithKline
0Calm
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors
Running, no new patientsPhase 1/242 patientsMain results: Jun 30, 2026
LLYLoxo Oncology, Inc.
0Calm
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Running, no new patientsPhase 3238 patientsMain results: Aug 29, 2023
BNTXBioNTech SE
0Calm
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
Signing up patientsPhase 260 patientsMain results: Oct 2028
MRKMerck Sharp & Dohme LLC
5Calm
A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)
Running, no new patientsPhase 2160 patientsMain results: Aug 18, 2026
GSKGlaxoSmithKline
0Calm
Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Running, no new patientsPhase 324 patientsMain results: Apr 3, 2024
PGENPrecigen, Inc
2Calm
PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
Signing up patientsPhase 224 patientsMain results: Nov 11, 2026
GSKGlaxoSmithKline
0Calm
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Running, no new patientsPhase 3494 patientsMain results: Oct 2, 2023
GSKGlaxoSmithKline
0Calm
China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Running, no new patientsPhase 372 patientsMain results: Apr 3, 2024
AMGNAmgen
2Calm
A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
FinishedPhase 1/253 patientsMain results: Feb 25, 2026
GSKGlaxoSmithKline
0Calm
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Signing up patientsPhase 3520 patientsMain results: Apr 28, 2031
REGNRegeneron Pharmaceuticals
5Calm
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
Running, no new patientsPhase 31,546 patientsMain results: Mar 12, 2026
REPLReplimune, Inc.
4Calm
Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
Running, no new patientsPhase 1/269 patientsMain results: Jul 2029
NVSNovartis Pharmaceuticals
5Calm
Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.
Signing up patientsPhase 220 patientsMain results: Feb 17, 2029
AZNAstraZeneca
0Calm
Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies
Running, no new patientsPhase 1/2105 patientsMain results: Dec 22, 2022
NVSNovartis Pharmaceuticals
5Calm
A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma
Running, no new patientsPhase 3109 patientsMain results: Jul 25, 2028
HURATuHURA Biosciences, Inc.
0Calm
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
Signing up patientsPhase 2/3118 patientsMain results: Mar 31, 2027
LLYEli Lilly and Company
0Calm
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
Running, no new patientsPhase 213 patientsMain results: May 2030
COGTCogent Biosciences, Inc.
0Calm
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
Running, no new patientsPhase 1/2110 patientsMain results: Mar 2027
JAZZJazz Pharmaceuticals
2Calm
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
Signing up patientsPhase 3510 patientsMain results: Jun 2028
PFEPfizer
0Calm
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
Running, no new patientsPhase 3854 patientsMain results: Aug 4, 2027
NVSNovartis Pharmaceuticals
5Calm
Ribociclib (LEE011) Rollover Study for Continued Access
Running, no new patientsPhase 222 patientsMain results: Feb 1, 2027
LLYEli Lilly and Company
0Calm
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Running, no new patientsPhase 1/2857 patientsMain results: Feb 14, 2025
BMYBristol-Myers Squibb
10Calm
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
FinishedPhase 267 patientsMain results: Feb 23, 2026
GILDKite, A Gilead Company
1Calm
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
Running, no new patientsPhase 3300 patientsMain results: Mar 2031
CNSPCNS Pharmaceuticals, Inc.
0Calm
A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme
Running, no new patientsPhase 2252 patientsMain results: Apr 27, 2026